Ensign Peak Advisors
VIGL

Ensign Peak Advisors’s Vigil Neuroscience VIGL Stock Holding History

Ensign Peak Advisors’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,578,116
Closed -$2.81M – 1720
2025
Q1 		$2.81M Buy
1,578,116
+875,000
+124% +$1.96M 0.01% 787
2024
Q4 		$1.2M Buy
703,116
+97,580
+16% +$288K ﹤0.01% 1209
2024
Q3 		$2.06M Buy
605,536
+210,420
+53% +$779K ﹤0.01% 938
2024
Q2 		$1.58M Buy
395,116
+166,442
+73% +$570K ﹤0.01% 1014
2024
Q1 		$780K Hold
228,674
– – ﹤0.01% 1475
2023
Q4 		$773K Buy
228,674
+216,750
+1,818% +$1.12M ﹤0.01% 1518
2023
Q3 		$64.3K Buy
+11,924
New +$82.4K ﹤0.01% 1747

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $109M AUM 317.92% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
6CM
683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $758M AUM 124.8% 1-Year Est. Return
HCM
Highbridge Capital Management New York $1.58B AUM 31.19% 1-Year Est. Return